Literature DB >> 27789714

18F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study.

Sae Jung Na1, Jin Kyoung Oh2, Seung Hyup Hyun3, Jeong Won Lee4, Il Ki Hong5, Bong-Il Song6, Tae-Sung Kim7, Jae Seon Eo8, Sung Won Lee9, Ie Ryung Yoo10, Yong An Chung11, Mijin Yun12.   

Abstract

Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) consists of a heterogeneous group of patients with a wide range of survival times, requiring further prognostic stratification to facilitate treatment allocation. We evaluated the prognostic value of 18F-FDG uptake on PET/CT at the time of presentation in patients with BCLC stage C HCC.
Methods: A total of 291 patients with BCLC stage C HCC who underwent 18F-FDG PET/CT between 2009 and 2010 for staging were retrospectively enrolled from 7 university hospitals. The patients were further divided into 2 groups according to the extent of disease, as intrahepatic or extrahepatic. Tumor-to-liver SUV ratio (TLR) of the primary tumor was measured on 18F-FDG PET/CT. Prognostic values of TLR and other clinical variables were analyzed to predict overall survival (OS) in univariate and multivariate analyses. Differences in the OS stratified by TLR were examined by the Kaplan-Meier method.
Results: Higher TLR was associated with extrahepatic disease (P = 0.018). On multivariate analysis, Child-Pugh classification and TLR were independent prognostic factors in the intrahepatic disease group (all P < 0.05), whereas TLR was the only independent prognostic factor in the extrahepatic disease group (P < 0.05). Patients with high TLR showed a significantly worse OS than those with low TLR (P < 0.05) in both groups.
Conclusion: In patients with BCLC stage C HCC, 18F-FDG uptake in the primary tumor was significantly higher in patients with extrahepatic disease than in those with intrahepatic disease. In addition, 18F-FDG uptake on pretreatment PET/CT had an incremental prognostic value for OS in both intrahepatic and extrahepatic disease groups.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-FDG; PET/CT; hepatocellular carcinoma; prognosis; survival

Mesh:

Substances:

Year:  2016        PMID: 27789714     DOI: 10.2967/jnumed.116.182022

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

2.  18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment.

Authors:  Pil Soo Sung; Hye Lim Park; Keungmo Yang; Seawon Hwang; Myeong Jun Song; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Ie Ryung Yoo; Si Hyun Bae
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-10       Impact factor: 9.236

3.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee; Seung Hyup Hyun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-02       Impact factor: 9.236

4.  Addition of [18 F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma.

Authors:  Binu V John; Sean Aubuchon; Bassam Dahman; Venkata Rajesh Konjeti; Douglas Heuman; Jennifer Hubert; Smitha Thomas; Yangyang Deng; Cynthia Solomon; Latha Thankam Sundaram; Eleanor Love; Amit G Singal; James L Tatum
Journal:  Liver Transpl       Date:  2020-05-08       Impact factor: 5.799

5.  18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Authors:  Mario Jreige; Periklis Mitsakis; Axel Van Der Gucht; Anastasia Pomoni; Marina Silva-Monteiro; Silvano Gnesin; Ariane Boubaker; Marie Nicod-Lalonde; Rafael Duran; John O Prior; Alban Denys; Niklaus Schaefer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-23       Impact factor: 9.236

6.  Diagnostic performance of total-body 18F-FDG PET/CT with fast 2-min acquisition for liver tumours: comparison with conventional PET/CT.

Authors:  Yan Hu; Guobing Liu; Haojun Yu; Jianying Gu; Hongcheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-28       Impact factor: 10.057

Review 7.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

8.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

Review 9.  18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma.

Authors:  Arno Kornberg; Martina Schernhammer; Helmut Friess
Journal:  J Clin Transl Hepatol       Date:  2017-07-08

10.  Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma.

Authors:  Hongping Xia; Jianxiang Chen; Hengjun Gao; Shik Nie Kong; Amudha Deivasigamani; Ming Shi; Tian Xie; Kam M Hui
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.